BRIEF-Neurobo Pharmaceuticals Completes Last Patient Last Visit In Its Phase 2A Clinical Trial Evaluating Da-1241 For The Treatment Of Mash

Reuters11-04

Nov 4 (Reuters) - Neurobo Pharmaceuticals Inc :

* NEUROBO PHARMACEUTICALS COMPLETES LAST PATIENT LAST VISIT IN ITS PHASE 2A CLINICAL TRIAL EVALUATING DA-1241 FOR THE TREATMENT OF MASH

* NEUROBO PHARMACEUTICALS INC - TOPLINE DATA READOUT EXPECTED IN DECEMBER 2024

Source text: Further company coverage:

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480658612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480658612","market":"us","top_or_hot":-1,"title":"BRIEF-Neurobo Pharmaceuticals Completes Last Patient Last Visit In Its Phase 2A Clinical Trial Evaluating Da-1241 For The Treatment Of Mash","media":"Reuters","content":"<html><body><p>Nov 4 (Reuters) - Neurobo Pharmaceuticals Inc   :</p><p>   * NEUROBO PHARMACEUTICALS COMPLETES LAST PATIENT LAST VISIT IN ITS PHASE 2A CLINICAL TRIAL EVALUATING DA-1241 FOR THE TREATMENT OF MASH</p><p>   * NEUROBO PHARMACEUTICALS INC - TOPLINE DATA READOUT EXPECTED IN DECEMBER 2024</p><p>Source text:    Further company coverage:   </p><p> (Reuters.Briefs@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurobo Pharmaceuticals Completes Last Patient Last Visit In Its Phase 2A Clinical Trial Evaluating Da-1241 For The Treatment Of Mash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurobo Pharmaceuticals Completes Last Patient Last Visit In Its Phase 2A Clinical Trial Evaluating Da-1241 For The Treatment Of Mash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 4 (Reuters) - Neurobo Pharmaceuticals Inc   :   * NEUROBO PHARMACEUTICALS COMPLETES LAST PATIENT LAST VISIT IN ITS PHASE 2A CLINICAL TRIAL EVALUATING DA-1241 FOR THE TREATMENT OF MASH   * NEUROBO ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRBO","symbol_name":"NeuroBo Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2480658612","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480658612","pubTimestamp":1730729867,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 4  - Neurobo Pharmaceuticals Inc   :   * NEUROBO PHARMACEUTICALS COMPLETES LAST PATIENT LAST VISIT IN ITS PHASE 2A CLINICAL TRIAL EVALUATING DA-1241 FOR THE TREATMENT OF MASH   * NEUROBO PHARMACEUTICALS INC - TOPLINE DATA READOUT EXPECTED IN DECEMBER 2024Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRBO":"NeuroBo Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"简介-Neurobo Pharmaceuticals在评估Da-1241治疗Mash的2A期临床试验中完成了最后一名患者的最后一次访视","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRBO":0.9},"content_text":"Nov 4 (Reuters) - Neurobo Pharmaceuticals Inc   :   * NEUROBO PHARMACEUTICALS COMPLETES LAST PATIENT LAST VISIT IN ITS PHASE 2A CLINICAL TRIAL EVALUATING DA-1241 FOR THE TREATMENT OF MASH   * NEUROBO PHARMACEUTICALS INC - TOPLINE DATA READOUT EXPECTED IN DECEMBER 2024Source text:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480658612"}